Korean J Clin Pharm.  2018 Sep;28(3):204-215. 10.24304/kjcp.2018.28.3.204.

The Effect of Metformin on Antipsychotic-induced Weight Gain in Patients with Schizophrenia or Schizoaffective Disorder: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials

Affiliations
  • 1College of Pharmacy, Duksung Women's University, Seoul 03169, Republic of Korea.
  • 2College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gyeongnam 50834, Republic of Korea. pusoon@inje.ac.kr

Abstract

BACKGROUND
In this systematic review and meta-analysis, the effect of metformin on weight loss was assessed to determine whether metformin should be recommended for the prevention or treatment of weight gain in patients receiving antipsychotic medication for the treatment of schizophrenia or schizoaffective disorder.
METHODS
The PubMed, Embase, and Cochrane Library databases were searched for all published randomized controlled trials (RCTs) from inception to June 2018. In addition, the references of relevant articles were also examined. Using Review Manager 5, the pooled estimates of the weighted mean difference (WMD) of the changes in body weight and body mass index (BMI) and the corresponding 95 % confidence intervals (CIs) were calculated.
RESULTS
The meta-analysis included 15 RCTs. The pooled analysis showed that compared with placebo, metformin led to significant reductions in body weight (WMD: −2.09, 95% CI: −2.59, −1.60; p<0.00001) and BMI (WMD: −0.90, 95% CI: −1.08, −0.72; p<0.00001). The effect of metformin on weight loss was greater in patients receiving olanzapine than in patients receiving clozapine (body weight, WMD: −2.39, 95% CI: −3.76, −1.02; p=0.0006 for olanzapine; −1.99, 95% C: −3.47, −0.51; p=0.009 for clozapine; BMI, WMD: −1.15, 95% CI: −1.74, −0.57, p=0.0001 for olanzapine; WMD: 0.76, 95% CI: −1.23, −0.28; p=0.002 for clozapine).
CONCLUSION
Metformin can be recommended to manage olanzapine-induced weight gain in patients with schizophrenia or schizoaffective disorder. The magnitude of the reductionss in body weight and BMI implieds that the use of metformin to attenuate olanzapine-induced weight gain can minimize the risk of coronary heart disease.

Keyword

Metformin; body weight; body mass index; schizophrenia; schizoaffective disorder

MeSH Terms

Body Mass Index
Body Weight
Clozapine
Coronary Disease
Humans
Metformin*
Psychotic Disorders*
Schizophrenia*
Weight Gain*
Weight Loss
Clozapine
Metformin
Full Text Links
  • KJCP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr